Schizophrenia as a systemic disease

Schizophrenia Bulletin

Volumn 35, Issue 2, 2009, Pages 381-382

  Kirkpatrick, Brian ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cognitive impairment; Diabetes; Inflammation; Movement disorders; Physical anomalies

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GLUCOSE TOLERANCE TEST; HEALTH CARE ACCESS; HUMAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SYSTEMIC DISEASE;

COGNITION DISORDERS; COMORBIDITY; DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 65349115000     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn183     Document Type: Article

References (19)

1. Dickinson W, Harvey P. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull. doi:10.1093/schbul/sbn097.
2. Whitty P, Waddington J, Owoeye O. Neurological signs and involuntary vovements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr Bull. doi:10.1093/schbul/sbnl26.
3. Buckley PF, Miller B, Lehrer Douglas, Castle D. Psychiatric comorbidities and the 'quicksand of symptomatology' in schizophrenia. Schizophr Bull. doi:10.1093/schbul/sbnl35.
4. Compton M, Walker E. Physical manifestations of neurode-velopmental disruption: what can minor physical anomalies tell us about chizophrenia? Schizophr Bull. doi:10.1093/ schbul/sbnl51.
5. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51:382-386.
6. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64-S66.
7. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289.
8. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 2007;24:481-485.
9. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients.J. Clin Psychiatry. 2004;65:1335-1342.
10. Fernandez-Egea E, Bernardo M, Donner T, et al. The metabolic profile of antipsychotic-naïve patients with nonaffective psychosis. Br J Psychiatry. In press.
11. Crespo-Facorro B, Carrasco-Marín E, Pérez-Iglesias R, et al. Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res. 2008;158:206-216.
12. Rapaport MH, Delrahim KK. An abbreviated review of immune abnormalities in schizophrenia. CNS Spectr. 2001 ;6: 392-397.
13. Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand. 1994;90:311-315.
14. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006;27:71-80.
15. Wahlbeck K, Forsén T, Osmond C, Barker DJ, Eriksson JG. Association of schizophrenia with low maternal body mass index, small size at birth, and thinness during childhood. Arch Gen Psychiatry. 2001;58:48-52.
16. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;8636:495.
17. Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirk-patrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res. 2008;98:302-306.
18. Fernandez-Egea E, Bernardo M, Parellada E, et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res. 2008;103:110-113.
19. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.